NBIX earnings call for the period ending June 30, 2020.
Motley Fool · 08/04 13:30
Credit Suisse Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $126
Credit Suisse analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and lowers the price target from $135 to $126.
Benzinga · 08/04 12:48
Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $146
Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $149 to $146.
Benzinga · 08/04 12:35
How Neurocrine Biosciences Crushed It in Q2
Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. Here's what you need to know about Neurocrine's impressive Q2 update. Neurocrine reported revenue of $302.
Motley Fool · 08/04 10:34
JP Morgan Downgrades Neurocrine Biosciences to Neutral, Announces $136 Price Target
JP Morgan analyst Anupam Rama downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Neutral and announces $136 price target.
Benzinga · 08/04 09:35
Neurocrine Bio beats Q2 views on strong Ingrezza sales
Neurocrine Biosciences (NASDAQ:NBIX) Q2 results: Revenues: $302.4M (+64.8%); Ingrezza sales: $267.6M (+48.2%). Net income: $79.6M (+55.2%); non-GAAP net in
seekingalpha · 08/04 02:02
Neurocrine Biosciences EPS beats by $0.40, beats on revenue
Neurocrine Biosciences (NASDAQ:NBIX): Q2 Non-GAAP EPS of $1.42 beats by $0.40; GAAP EPS of $0.81 beats by $0.15. Revenue of $302.4M (+64.7% Y/Y) beats by $
seekingalpha · 08/04 01:02
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?